Inclusion Criteria:

        Histologically or cytologically confirmed Triple-Negative invasive breast carcinoma

          -  Clinical stageIIA-IIIB

          -  Patients must have measurable disease as defined by palpable lesion with caliper
             and/or a positive mammogram or ultrasound. Bilateral mammogram and clip placement is
             required for study entry. Baseline measurements of the indicator lesions must be
             recorded on the Patient Registration Form. To be valid for baseline, the measurements
             must have been made within the 14 days if palpable. If not palpable, a mammogram or
             MRI must be done within 14 days. If palpable, a mammogram or MRI must be done within 2
             months prior to study entry. If clinically indicated, x-rays and scans must be done
             within 28 days of study entry.

          -  Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of
             study entry

          -  Signed informed consent

          -  Adequate organ function within 2 weeks of study entry: Absolute neutrophil count
             >1500/mm3, Hgb >9.0 g/dl and platelet count >100,000/mm3 Total bilirubin < upper limit
             of normal Creatinine < 1.5 mg/dL or calculated cranial cruciate ligament (CrCL)
             >50mL/min using the Cockcroft Gault equation serum glutamate oxaloacetate
             transaminase(SGOT)(AST) or serum glutamic oxaloacetic transaminase(SGPT)(ALT) and
             Alkaline Phosphatase must be within the range allowing for eligibility

          -  Patients must be over 18 years old

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of treatment

          -  Women of childbearing potential and men must agree to use adequate contraception
             (barrier method of birth control) prior to study entry and for the duration of study
             participation.

        Exclusion Criteria:

          -  Metastatic disease

          -  Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent,
             targeted therapy or radiation therapy for current breast cancer. Patients with history
             of breast cancer greater than 5 years from initial diagnosis are eligible for the
             study. Patients may not have received anthracycline-based chemotherapy in the past.
             Patients with history of ductal carcinoma in situ(DCIS) are eligible if there were
             treated with surgery alone.

          -  History of previous or current malignancy at other sites with the exception of
             adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma
             of the skin. Patients with a history of other malignancies, who remain disease free
             for greater than five years are eligible.